首页 > 市场调查报告书 > 製药

处方药

市场调查报告书

商品编码

1855084

偏头痛处方药市场报告：趋势、预测和竞争分析（至2031年）

Prescription Migraine Medicine Market Report: Trends, Forecast and Competitive Analysis to 2031

出版日期: 2025年10月28日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录图表

全球偏头痛处方药市场前景广阔，主要得益于医院、诊所和药局市场的发展机会。预计2025年至2031年，全球偏头痛处方药市场将以9.9%的复合年增长率成长。推动该市场成长的关键因素包括治疗方案的进步、公众意识的提高和诊断水平的提升，以及疗效和患者预后的改善。

Lucintel 预测，由于Sumatriptan市场供应广泛、剂型多样以及先发优势，按类型划分，预计在预测期内将实现高速成长。
从应用角度来看，由于药品的可及性、便利性以及非处方药和处方笺的组合，预计药局将实现强劲成长。
从地区来看，预计北美在预测期内将出现最高成长，因为美国是全球偏头痛发病率最高的国家之一。

偏头痛处方药市场的新趋势

处方偏头痛药物市场正受到多种新兴趋势的影响，这些趋势反映了医学的进步和患者偏好的改变。这些趋势正在推动创新，改善治疗效果，并扩大治疗的可近性。

生技药品和CGRP抑制剂：CGRP抑制剂的出现代表着偏头痛治疗领域的重大突破。诸如依明和Agility等生物製药靶向抑钙素基因相关胜肽（CGRP）受体，该受体在偏头痛的发生和发展过程中起着关键作用。这类药物能够提供预防性治疗，且副作用比传统药物更少，这代表着偏头痛治疗方式的模式转移。
远端医疗和数位健康：远端医疗和数位健康平台的日益普及正在改变偏头痛的治疗方式。与专家的虚拟咨询使患者更容易获得处方笺治疗，尤其是在医疗资源匮乏的地区。此外，数位偏头痛追踪工具可帮助患者和医生更了解偏头痛的诱因、发作频率和严重程度，从而做出更明智的治疗决策。
精准医疗：偏头痛治疗的个人化方法正在兴起。基因检测和个人化治疗方案使医生能够根据患者独特的基因和生活方式因素，开立更有效的药物。这种量身订製的方法可以改善治疗效果，并减少偏头痛药物处方过程中反覆试验。
预防性治疗：市场格局正在重塑，重点从治疗偏头痛症状转向预防偏头痛。随着患者和医疗保健提供者寻求长期降低偏头痛发作频率和严重程度，包括CGRP抑制剂和肉毒桿菌注射在内的预防性药物正变得越来越普遍。
非处方药（OTC）整合：非处方药与处方药的整合是新兴趋势。许多患者使用非处方药，例如非类固醇消炎剂，来缓解急性症状，而医生也越来越多地将非处方药和处方药结合使用，以提供更全面的治疗方案。这一趋势凸显了整合多种治疗方案的综合护理模式的必要性。

随着更有效、更具针对性的疗法的引入和普及，这些趋势正在改变偏头痛的治疗方法模式。生物製药和个人化医疗的兴起，将使患者受益于更个人化和有效的治疗，而远端医疗和预防性措施将提高就医的便利性和长期护理水平。

偏头痛处方药市场的最新趋势

处方偏头痛市场正经历多项重大发展，每一项都有助于改善治疗方案和患者疗效。这些发展得益于药物创新、以病人为中心的治疗方案以及新的监管核准。

CGRP抑制剂的核准：CGRP抑制剂（例如aim、Agility和Agony）的核准彻底改变了偏头痛的治疗方式。由于与传统药物相比副作用较少，且具有预防性治疗的潜力，这些疗法的应用日益广泛。这些生物製药尤其适用于慢性偏头痛患者以及传统疗法效果不佳的患者。
远端医疗的普及：远端医疗的兴起使偏头痛治疗更加便捷，患者无需亲自就诊即可获得专家的咨询和处方。这项发展对于偏远和医疗资源匮乏地区的患者尤其重要，因为这些地区获得专科医疗服务的机会有限。
联合治疗：联合治疗，例如将曲坦类药物与止吐药和预防性药物合併使用，正变得越来越普遍。这些多重药物合併联合治疗旨在同时缓解急性症状和长期预防，为偏头痛管理提供更全面的方案。
新型预防药物：新型预防药物正在上市，为患者提供新的长期治疗选择。肉毒桿菌毒素（Botox）曾主要用于美容用途，如今已核准用于预防慢性偏头痛，这表明其他医学研究领域也可能涌现出新的治疗方法。
监管变化：包括美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 在内的全球监管机构正在加快核准新的偏头痛治疗药物。这些核准促成了诸如瑞普坦 (Repent) 和单株抗体等新型疗法的问世，使患者能够获得更有效、更有针对性的治疗。

这些重大进展正在扩大偏头痛患者的治疗选择范围，并改善急性期治疗和预防性治疗。 CGRP抑制剂、新型联合治疗和预防性药物的引入正在重塑市场格局，为患者提供更有效、更个人化的偏头痛管理方案。

The future of the global prescription migraine medicine market looks promising with opportunities in the hospital, clinic, and drug store markets. The global prescription migraine medicine market is expected to grow with a CAGR of 9.9% from 2025 to 2031. The major drivers for this market are advances in treatment options, increased awareness and diagnosis, and improved efficacy and patient outcomes.

Lucintel forecasts that, within the type category, sumatriptan is expected to witness higher growth over the forecast period due to wide market availability, variety of forms, first-mover advantage.
Within the application category, drug store is expected to witness the higher growth due to access and convenience, otc and prescription combination.
In terms of region, North America is expected to witness the highest growth over the forecast period due to the u.s. has one of the highest rates of migraine prevalence globally.

Emerging Trends in the Prescription Migraine Medicine Market

The prescription migraine medicine market is being shaped by several emerging trends, which reflect both advancements in medical science and shifts in patient preferences. These trends are driving innovation, improving treatment outcomes, and expanding access to care.

Biologics and CGRP Inhibitors: The rise of CGRP inhibitors represents a significant breakthrough in migraine treatment. These biologics, such as aiming and Agility, target the calcitonin gene-related peptide (CGRP) receptor, a key player in the migraine process. This class of drugs offers preventive treatment with fewer side effects compared to traditional medications, creating a paradigm shift in how migraines are treated.
Telemedicine and Digital Health: The increasing use of telemedicine and digital health platforms is transforming migraine care. Virtual consultations with specialists have made it easier for patients to access prescription treatments, especially in underserved areas. Moreover, digital migraine tracking tools help both patients and doctors better understand triggers, frequency, and severity, leading to more informed treatment decisions.
Personalized Medicine: Personalized approaches to migraine treatment are on the rise. Genetic testing and individualized treatment plans allow doctors to prescribe medications that are more likely to work based on the patient's specific genetic and lifestyle factors. This tailored approach enhances treatment outcomes and reduces the trial-and-error nature of prescribing migraine medications.
Preventive Treatments: The growing emphasis on preventing migraines, rather than just treating symptoms, is reshaping the market. Preventive medications, including CGRP inhibitors and Botox injections, are becoming more common as patients and healthcare providers seek to reduce the frequency and severity of migraines over the long term.
Over-the-Counter (OTC) Integration: The integration of OTC solutions with prescription treatments is an emerging trend. Many patients use OTC medications like NSAIDs to manage acute symptoms, and doctors are increasingly combining these with prescription therapies for a more comprehensive approach. This trend emphasizes the need for integrated care models that combine multiple therapeutic options.

These trends are transforming the migraine treatment landscape by introducing more effective, targeted therapies and improving accessibility. As biologics and personalized medicine gain traction, patients will benefit from more tailored, effective treatments, while telemedicine and preventive approaches will increase convenience and long-term care.

Recent Developments in the Prescription Migraine Medicine Market

The prescription migraine medicine market has witnessed several key developments, each contributing to the advancement of treatment options and improving patient outcomes. These developments are driven by pharmaceutical innovation, patient-centric approaches, and new regulatory approvals.

CGRP Inhibitors Approval: The approval of CGRP inhibitors like aiming, Agility, and Agony has revolutionized the treatment of migraine. These drugs offer preventive treatment with fewer side effects compared to traditional medications, which has led to their increased adoption. These biologics are particularly beneficial for patients with chronic migraines and those who do not respond well to conventional treatments.
Telemedicine Adoption: The rise of telemedicine has made migraine care more accessible, allowing patients to receive consultations and prescriptions from specialists without the need for in-person visits. This development is especially significant for individuals in rural or underserved areas where access to specialized care is limited.
Combination Therapies: Combination therapies, such as the pairing of trip tans with anti-nausea medications or preventive treatments, are becoming more common. These multi-drug strategies aim to address both acute symptoms and long-term prevention, providing a more comprehensive approach to managing migraines.
Emerging Preventive Medications: New preventive medications are entering the market, offering patients additional options for long-term management. Botox, once used primarily for cosmetic purposes, is now approved for chronic migraine prevention, demonstrating the potential for new treatments to emerge from other areas of medical research.
Regulatory Changes: Regulatory bodies around the world, including the FDA and EMA, have been approving new migraine treatments at a faster pace. These approvals have led to the introduction of novel therapies, such as repents and monoclonal antibodies, which offer more effective and targeted treatments for patients.

These key developments are expanding the range of treatments available to migraine sufferers, improving both acute and preventive care. The introduction of CGRP inhibitors, new combination therapies, and preventive medications is reshaping the market, providing patients with more effective and personalized options for managing migraines.

Strategic Growth Opportunities in the Prescription Migraine Medicine Market

The prescription migraine medicine market offers numerous strategic growth opportunities, particularly in areas that cater to emerging patient needs and capitalize on innovations in drug development. Key growth opportunities include expanding access to new medications, leveraging digital health technologies, and addressing unmet needs in migraine care.

Expanding Access to CGRP Inhibitors: As CGRP inhibitors become more widely available, pharmaceutical companies have the opportunity to increase market penetration by offering these drugs at competitive prices or through insurance programs. Expanding access to these medications, particularly in emerging markets, could significantly boost sales and improve global migraine care.
Telemedicine for Remote Consultations: The continued growth of telemedicine presents an opportunity to enhance access to prescription migraine treatments. Virtual consultations, symptom tracking apps, and online pharmacies are making it easier for patients to receive care, especially in rural and underserved areas.
Combination Therapy Development: There is a growing opportunity in developing combination therapies that combine acute and preventive medications in a single treatment regimen. These therapies offer a more comprehensive approach to migraine management, improving patient compliance and outcomes.
Expanding Preventive Treatment Options: With the increasing demand for preventive treatments, pharmaceutical companies can capitalize on developing and marketing new drugs aimed at preventing migraines. Expanding the range of preventive medications will address the needs of patients who experience frequent and debilitating migraines.
Personalized Medicine Approaches: Developing personalized treatment plans based on genetic and lifestyle factors offers a significant opportunity for growth. By offering treatments that are more effective and tailored to individual patients, companies can improve treatment outcomes and patient satisfaction.

These strategic growth opportunities are reshaping the migraine medicine market, driving innovation and expanding access to effective treatments. By focusing on personalized care, expanding access to preventive options, and leveraging digital health technologies, the industry can meet the growing demand for better migraine management solutions.

Prescription Migraine Medicine Market Driver and Challenges

The prescription migraine medicine market is shaped by various drivers and challenges, which include technological advancements, regulatory factors, and the evolving needs of patients. Understanding these factors is crucial for navigating the market dynamics.

The factors responsible for driving the Prescription Migraine Medicine market include:

1. Technological Advancements: Advances in biotechnology and drug development have led to the creation of more targeted and effective migraine treatments, such as CGRP inhibitors. These innovations improve treatment outcomes and offer better options for patients with chronic migraines.

2. Increasing Awareness of Migraine: Rising awareness of migraine as a serious medical condition has led to increased demand for prescription treatments. As more people recognize the impact of migraines on quality of life, they are seeking medical solutions, driving market growth.

3. Preventive Care Demand: There is a growing demand for preventive treatments to reduce the frequency and severity of migraines. Preventive drugs, such as CGRP inhibitors and Botox, are gaining popularity, reflecting a shift toward long-term management rather than just symptomatic relief.

4. Personalized Medicine: The move toward personalized medicine is driving growth in the market. By tailoring treatments to individual patients based on their genetic profiles and lifestyle factors, healthcare providers can offer more effective migraine therapies.

5. Healthcare Access Expansion: Expanding healthcare access, especially in emerging markets, is helping to drive the growth of the prescription migraine medicine market. Increased healthcare infrastructure and the availability of health insurance are making migraine treatments more accessible.

Challenges in the Prescription Migraine Medicine market are:

1. Cost and Affordability: One of the major challenges is the high cost of newer migraine treatments, such as CGRP inhibitors, which may not be affordable for all patients. This limits access to these medications, particularly in developing markets.

2. Regulatory Hurdles: Regulatory approval processes for new drugs can be lengthy and expensive. This can delay the introduction of new treatments and limit the options available to patients.

3. Treatment Adherence: Ensuring that patients adhere to prescribed treatment regimens can be challenging, particularly when medications are expensive or have complex dosing schedules.

The prescription migraine medicine market is driven by technological advancements, increasing demand for preventive treatments, and personalized care, while challenges such as cost and regulatory hurdles need to be addressed to ensure continued growth and patient access.

List of Prescription Migraine Medicine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies prescription migraine medicine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the prescription migraine medicine companies profiled in this report include-

Gsk
Teva
Pfizer
Amgen
Viatris
Allergan
Grunenthal

Prescription Migraine Medicine Market by Segment

The study includes a forecast for the global prescription migraine medicine market by type, application, and region.

Prescription Migraine Medicine Market by Type [Value from 2019 to 2031]:

Sumatriptan
Rizatriptan
Others

Prescription Migraine Medicine Market by Application [Value from 2019 to 2031]:

Hospital
Clinic
Drug Store

Prescription Migraine Medicine Market by Region [Value from 2019 to 2031]:

North America
Europe
Asia Pacific
The Rest of the World

Country Wise Outlook for the Prescription Migraine Medicine Market

The prescription migraine medicine market is undergoing rapid evolution, driven by advances in pharmacology, the rise of biologics, and a growing focus on personalized medicine. As the understanding of migraine pathophysiology improves, new treatments are emerging to provide better relief for patients. Key markets such as the United States, China, Germany, India, and Japan are seeing significant progress in the development and availability of migraine medications, expanding treatment options for patients.

United States: The U.S. market has seen significant progress with the approval and growing adoption of CGRP inhibitors, a new class of biologics that target a protein involved in migraine attacks. Drugs like aiming, Agility, and Agony are being prescribed for preventive treatment, marking a shift from traditional trip tans. The rise of telemedicine has also improved patient access to migraine specialists, helping many patients receive timely prescriptions. Furthermore, the focus on personalized medicine is increasing, with doctors adjusting treatments based on the individual's response and genetic profile.
China: In China, the prescription migraine medicine market is still emerging, but growing awareness of the condition is driving demand for better treatments. While trip tans remain the mainstay of treatment, the approval of newer medications, including CGRP inhibitors, is gaining traction. Chinese authorities have been working to expand access to migraine treatments, though affordability and healthcare infrastructure remain challenges. There is also increasing interest in integrating traditional Chinese medicine (TCM) with modern pharmacological treatments to address migraine symptoms, combining both approaches to cater to different patient preferences.
Germany: Germany has a well-established migraine treatment landscape, with a strong emphasis on a combination of pharmacological and non-pharmacological therapies. The prescription market in Germany is expanding with the introduction of CGRP inhibitors and newer trip tans. There is an increasing trend toward precision medicine, with doctors prescribing treatments based on individual migraine profiles and genetic markers. Germany also benefits from a robust healthcare system, which ensures that advanced treatments, such as biologics, are accessible to a wider population.
India: In India, the market for prescription migraine medications is growing, but many patients still rely on over-the-counter (OTC) solutions due to cost considerations. However, awareness of migraines as a serious medical condition is on the rise, which is driving demand for prescription treatments. Triptans are commonly prescribed, but newer drugs such as CGRP inhibitors are slowly entering the market, particularly in urban centers. Economic factors influence the adoption of newer treatments, with a preference for affordable options being prevalent in rural areas.
Japan: Japan's migraine medicine market is seeing rapid advancements with a strong preference for traditional medicines alongside modern pharmacotherapies. CGRP inhibitors have been introduced, but their use is more common in specialized centers due to their high cost. Japan also has a unique approach to personalized migraine treatment, using detailed patient records to inform decisions on drug selection. Additionally, there is increasing awareness of the need for preventive treatments, which is driving the demand for newer and more effective medications.

Features of the Global Prescription Migraine Medicine Market

Market Size Estimates: Prescription migraine medicine market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Prescription migraine medicine market size by type, application, and region in terms of value ($B).
Regional Analysis: Prescription migraine medicine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the prescription migraine medicine market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the prescription migraine medicine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the prescription migraine medicine market by type (sumatriptan, rizatriptan, and others), application (hospital, clinic, and drug store), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Market Overview

2.1 Background and Classifications
2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment

4. Global Prescription Migraine Medicine Market by Type

4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 Sumatriptan: Trends and Forecast (2019-2031)
4.4 Rizatriptan: Trends and Forecast (2019-2031)
4.5 Others: Trends and Forecast (2019-2031)

5. Global Prescription Migraine Medicine Market by Application

5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 Hospital: Trends and Forecast (2019-2031)
5.4 Clinic: Trends and Forecast (2019-2031)
5.5 Drug Store: Trends and Forecast (2019-2031)

6. Regional Analysis

6.1 Overview
6.2 Global Prescription Migraine Medicine Market by Region

7. North American Prescription Migraine Medicine Market

7.1 Overview
7.2 North American Prescription Migraine Medicine Market by type
7.3 North American Prescription Migraine Medicine Market by application
7.4 United States Prescription Migraine Medicine Market
7.5 Mexican Prescription Migraine Medicine Market
7.6 Canadian Prescription Migraine Medicine Market

8. European Prescription Migraine Medicine Market

8.1 Overview
8.2 European Prescription Migraine Medicine Market by type
8.3 European Prescription Migraine Medicine Market by application
8.4 German Prescription Migraine Medicine Market
8.5 French Prescription Migraine Medicine Market
8.6 Spanish Prescription Migraine Medicine Market
8.7 Italian Prescription Migraine Medicine Market
8.8 United Kingdom Prescription Migraine Medicine Market

9. APAC Prescription Migraine Medicine Market

9.1 Overview
9.2 APAC Prescription Migraine Medicine Market by type
9.3 APAC Prescription Migraine Medicine Market by application
9.4 Japanese Prescription Migraine Medicine Market
9.5 Indian Prescription Migraine Medicine Market
9.6 Chinese Prescription Migraine Medicine Market
9.7 South Korean Prescription Migraine Medicine Market
9.8 Indonesian Prescription Migraine Medicine Market

10. ROW Prescription Migraine Medicine Market

10.1 Overview
10.2 ROW Prescription Migraine Medicine Market by type
10.3 ROW Prescription Migraine Medicine Market by application
10.4 Middle Eastern Prescription Migraine Medicine Market
10.5 South American Prescription Migraine Medicine Market
10.6 African Prescription Migraine Medicine Market

11. Competitor Analysis

11.1 Product Portfolio Analysis
11.2 Operational Integration
11.3 Porter's Five Forces Analysis
- Competitive Rivalry
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat of Substitutes
- Threat of New Entrants
11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

12.1 Value Chain Analysis
12.2 Growth Opportunity Analysis
- 12.2.1 Growth Opportunities by Type
- 12.2.2 Growth Opportunities by Application
12.3 Emerging Trends in the Global Prescription Migraine Medicine Market
12.4 Strategic Analysis
- 12.4.1 New Product Development
- 12.4.2 Certification and Licensing
- 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

13.1 Competitive Analysis
13.2 Gsk
- Company Overview
- Prescription Migraine Medicine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.3 Teva
- Company Overview
- Prescription Migraine Medicine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.4 Pfizer
- Company Overview
- Prescription Migraine Medicine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.5 Amgen
- Company Overview
- Prescription Migraine Medicine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.6 Viatris
- Company Overview
- Prescription Migraine Medicine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.7 Allergan
- Company Overview
- Prescription Migraine Medicine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.8 Grunenthal
- Company Overview
- Prescription Migraine Medicine Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing

14. Appendix

14.1 List of Figures
14.2 List of Tables
14.3 Research Methodology
14.4 Disclaimer
14.5 Copyright
14.6 Abbreviations and Technical Units
14.7 About Us
14.8 Contact Us

简介目录图表

List of Figures

Figure 1.1: Trends and Forecast for the Global Prescription Migraine Medicine Market
Figure 2.1: Usage of Prescription Migraine Medicine Market
Figure 2.2: Classification of the Global Prescription Migraine Medicine Market
Figure 2.3: Supply Chain of the Global Prescription Migraine Medicine Market
Figure 3.1: Driver and Challenges of the Prescription Migraine Medicine Market
Figure 3.2: PESTLE Analysis
Figure 3.3: Patent Analysis
Figure 3.4: Regulatory Environment
Figure 4.1: Global Prescription Migraine Medicine Market by Type in 2019, 2024, and 2031
Figure 4.2: Trends of the Global Prescription Migraine Medicine Market ($B) by Type
Figure 4.3: Forecast for the Global Prescription Migraine Medicine Market ($B) by Type
Figure 4.4: Trends and Forecast for Sumatriptan in the Global Prescription Migraine Medicine Market (2019-2031)
Figure 4.5: Trends and Forecast for Rizatriptan in the Global Prescription Migraine Medicine Market (2019-2031)
Figure 4.6: Trends and Forecast for Others in the Global Prescription Migraine Medicine Market (2019-2031)
Figure 5.1: Global Prescription Migraine Medicine Market by Application in 2019, 2024, and 2031
Figure 5.2: Trends of the Global Prescription Migraine Medicine Market ($B) by Application
Figure 5.3: Forecast for the Global Prescription Migraine Medicine Market ($B) by Application
Figure 5.4: Trends and Forecast for Hospital in the Global Prescription Migraine Medicine Market (2019-2031)
Figure 5.5: Trends and Forecast for Clinic in the Global Prescription Migraine Medicine Market (2019-2031)
Figure 5.6: Trends and Forecast for Drug Store in the Global Prescription Migraine Medicine Market (2019-2031)
Figure 6.1: Trends of the Global Prescription Migraine Medicine Market ($B) by Region (2019-2024)
Figure 6.2: Forecast for the Global Prescription Migraine Medicine Market ($B) by Region (2025-2031)
Figure 7.1: North American Prescription Migraine Medicine Market by type in 2019, 2024, and 2031
Figure 7.2: Trends of the North American Prescription Migraine Medicine Market ($B) by type (2019-2024)
Figure 7.3: Forecast for the North American Prescription Migraine Medicine Market ($B) by type (2025-2031)
Figure 7.4: North American Prescription Migraine Medicine Market by application in 2019, 2024, and 2031
Figure 7.5: Trends of the North American Prescription Migraine Medicine Market ($B) by application (2019-2024)
Figure 7.6: Forecast for the North American Prescription Migraine Medicine Market ($B) by application (2025-2031)
Figure 7.7: Trends and Forecast for the United States Prescription Migraine Medicine Market ($B) (2019-2031)
Figure 7.8: Trends and Forecast for the Mexican Prescription Migraine Medicine Market ($B) (2019-2031)
Figure 7.9: Trends and Forecast for the Canadian Prescription Migraine Medicine Market ($B) (2019-2031)
Figure 8.1: European Prescription Migraine Medicine Market by type in 2019, 2024, and 2031
Figure 8.2: Trends of the European Prescription Migraine Medicine Market ($B) by type (2019-2024)
Figure 8.3: Forecast for the European Prescription Migraine Medicine Market ($B) by type (2025-2031)
Figure 8.4: European Prescription Migraine Medicine Market by application in 2019, 2024, and 2031
Figure 8.5: Trends of the European Prescription Migraine Medicine Market ($B) by application (2019-2024)
Figure 8.6: Forecast for the European Prescription Migraine Medicine Market ($B) by application (2025-2031)
Figure 8.7: Trends and Forecast for the German Prescription Migraine Medicine Market ($B) (2019-2031)
Figure 8.8: Trends and Forecast for the French Prescription Migraine Medicine Market ($B) (2019-2031)
Figure 8.9: Trends and Forecast for the Spanish Prescription Migraine Medicine Market ($B) (2019-2031)
Figure 8.10: Trends and Forecast for the Italian Prescription Migraine Medicine Market ($B) (2019-2031)
Figure 8.11: Trends and Forecast for the United Kingdom Prescription Migraine Medicine Market ($B) (2019-2031)
Figure 9.1: APAC Prescription Migraine Medicine Market by type in 2019, 2024, and 2031
Figure 9.2: Trends of the APAC Prescription Migraine Medicine Market ($B) by type (2019-2024)
Figure 9.3: Forecast for the APAC Prescription Migraine Medicine Market ($B) by type (2025-2031)
Figure 9.4: APAC Prescription Migraine Medicine Market by application in 2019, 2024, and 2031
Figure 9.5: Trends of the APAC Prescription Migraine Medicine Market ($B) by application (2019-2024)
Figure 9.6: Forecast for the APAC Prescription Migraine Medicine Market ($B) by application (2025-2031)
Figure 9.7: Trends and Forecast for the Japanese Prescription Migraine Medicine Market ($B) (2019-2031)
Figure 9.8: Trends and Forecast for the Indian Prescription Migraine Medicine Market ($B) (2019-2031)
Figure 9.9: Trends and Forecast for the Chinese Prescription Migraine Medicine Market ($B) (2019-2031)
Figure 9.10: Trends and Forecast for the South Korean Prescription Migraine Medicine Market ($B) (2019-2031)
Figure 9.11: Trends and Forecast for the Indonesian Prescription Migraine Medicine Market ($B) (2019-2031)
Figure 10.1: ROW Prescription Migraine Medicine Market by type in 2019, 2024, and 2031
Figure 10.2: Trends of the ROW Prescription Migraine Medicine Market ($B) by type (2019-2024)
Figure 10.3: Forecast for the ROW Prescription Migraine Medicine Market ($B) by type (2025-2031)
Figure 10.4: ROW Prescription Migraine Medicine Market by application in 2019, 2024, and 2031
Figure 10.5: Trends of the ROW Prescription Migraine Medicine Market ($B) by application (2019-2024)
Figure 10.6: Forecast for the ROW Prescription Migraine Medicine Market ($B) by application (2025-2031)
Figure 10.7: Trends and Forecast for the Middle Eastern Prescription Migraine Medicine Market ($B) (2019-2031)
Figure 10.8: Trends and Forecast for the South American Prescription Migraine Medicine Market ($B) (2019-2031)
Figure 10.9: Trends and Forecast for the African Prescription Migraine Medicine Market ($B) (2019-2031)
Figure 11.1: Porter's Five Forces Analysis of the Global Prescription Migraine Medicine Market
Figure 11.2: Market Share (%) of Top Players in the Global Prescription Migraine Medicine Market (2024)
Figure 12.1: Growth Opportunities for the Global Prescription Migraine Medicine Market by Type
Figure 12.2: Growth Opportunities for the Global Prescription Migraine Medicine Market by Application
Figure 12.3: Growth Opportunities for the Global Prescription Migraine Medicine Market by Region
Figure 12.4: Emerging Trends in the Global Prescription Migraine Medicine Market

List of Tables

Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Prescription Migraine Medicine Market by Type and Application
Table 1.2: Attractiveness Analysis for the Prescription Migraine Medicine Market by Region
Table 1.3: Global Prescription Migraine Medicine Market Parameters and Attributes
Table 3.1: Trends of the Global Prescription Migraine Medicine Market (2019-2024)
Table 3.2: Forecast for the Global Prescription Migraine Medicine Market (2025-2031)
Table 4.1: Attractiveness Analysis for the Global Prescription Migraine Medicine Market by Type
Table 4.2: Market Size and CAGR of Various Type in the Global Prescription Migraine Medicine Market (2019-2024)
Table 4.3: Market Size and CAGR of Various Type in the Global Prescription Migraine Medicine Market (2025-2031)
Table 4.4: Trends of Sumatriptan in the Global Prescription Migraine Medicine Market (2019-2024)
Table 4.5: Forecast for Sumatriptan in the Global Prescription Migraine Medicine Market (2025-2031)
Table 4.6: Trends of Rizatriptan in the Global Prescription Migraine Medicine Market (2019-2024)
Table 4.7: Forecast for Rizatriptan in the Global Prescription Migraine Medicine Market (2025-2031)
Table 4.8: Trends of Others in the Global Prescription Migraine Medicine Market (2019-2024)
Table 4.9: Forecast for Others in the Global Prescription Migraine Medicine Market (2025-2031)
Table 5.1: Attractiveness Analysis for the Global Prescription Migraine Medicine Market by Application
Table 5.2: Market Size and CAGR of Various Application in the Global Prescription Migraine Medicine Market (2019-2024)
Table 5.3: Market Size and CAGR of Various Application in the Global Prescription Migraine Medicine Market (2025-2031)
Table 5.4: Trends of Hospital in the Global Prescription Migraine Medicine Market (2019-2024)
Table 5.5: Forecast for Hospital in the Global Prescription Migraine Medicine Market (2025-2031)
Table 5.6: Trends of Clinic in the Global Prescription Migraine Medicine Market (2019-2024)
Table 5.7: Forecast for Clinic in the Global Prescription Migraine Medicine Market (2025-2031)
Table 5.8: Trends of Drug Store in the Global Prescription Migraine Medicine Market (2019-2024)
Table 5.9: Forecast for Drug Store in the Global Prescription Migraine Medicine Market (2025-2031)
Table 6.1: Market Size and CAGR of Various Regions in the Global Prescription Migraine Medicine Market (2019-2024)
Table 6.2: Market Size and CAGR of Various Regions in the Global Prescription Migraine Medicine Market (2025-2031)
Table 7.1: Trends of the North American Prescription Migraine Medicine Market (2019-2024)
Table 7.2: Forecast for the North American Prescription Migraine Medicine Market (2025-2031)
Table 7.3: Market Size and CAGR of Various type in the North American Prescription Migraine Medicine Market (2019-2024)
Table 7.4: Market Size and CAGR of Various type in the North American Prescription Migraine Medicine Market (2025-2031)
Table 7.5: Market Size and CAGR of Various application in the North American Prescription Migraine Medicine Market (2019-2024)
Table 7.6: Market Size and CAGR of Various application in the North American Prescription Migraine Medicine Market (2025-2031)
Table 7.7: Trends and Forecast for the United States Prescription Migraine Medicine Market (2019-2031)
Table 7.8: Trends and Forecast for the Mexican Prescription Migraine Medicine Market (2019-2031)
Table 7.9: Trends and Forecast for the Canadian Prescription Migraine Medicine Market (2019-2031)
Table 8.1: Trends of the European Prescription Migraine Medicine Market (2019-2024)
Table 8.2: Forecast for the European Prescription Migraine Medicine Market (2025-2031)
Table 8.3: Market Size and CAGR of Various type in the European Prescription Migraine Medicine Market (2019-2024)
Table 8.4: Market Size and CAGR of Various type in the European Prescription Migraine Medicine Market (2025-2031)
Table 8.5: Market Size and CAGR of Various application in the European Prescription Migraine Medicine Market (2019-2024)
Table 8.6: Market Size and CAGR of Various application in the European Prescription Migraine Medicine Market (2025-2031)
Table 8.7: Trends and Forecast for the German Prescription Migraine Medicine Market (2019-2031)
Table 8.8: Trends and Forecast for the French Prescription Migraine Medicine Market (2019-2031)
Table 8.9: Trends and Forecast for the Spanish Prescription Migraine Medicine Market (2019-2031)
Table 8.10: Trends and Forecast for the Italian Prescription Migraine Medicine Market (2019-2031)
Table 8.11: Trends and Forecast for the United Kingdom Prescription Migraine Medicine Market (2019-2031)
Table 9.1: Trends of the APAC Prescription Migraine Medicine Market (2019-2024)
Table 9.2: Forecast for the APAC Prescription Migraine Medicine Market (2025-2031)
Table 9.3: Market Size and CAGR of Various type in the APAC Prescription Migraine Medicine Market (2019-2024)
Table 9.4: Market Size and CAGR of Various type in the APAC Prescription Migraine Medicine Market (2025-2031)
Table 9.5: Market Size and CAGR of Various application in the APAC Prescription Migraine Medicine Market (2019-2024)
Table 9.6: Market Size and CAGR of Various application in the APAC Prescription Migraine Medicine Market (2025-2031)
Table 9.7: Trends and Forecast for the Japanese Prescription Migraine Medicine Market (2019-2031)
Table 9.8: Trends and Forecast for the Indian Prescription Migraine Medicine Market (2019-2031)
Table 9.9: Trends and Forecast for the Chinese Prescription Migraine Medicine Market (2019-2031)
Table 9.10: Trends and Forecast for the South Korean Prescription Migraine Medicine Market (2019-2031)
Table 9.11: Trends and Forecast for the Indonesian Prescription Migraine Medicine Market (2019-2031)
Table 10.1: Trends of the ROW Prescription Migraine Medicine Market (2019-2024)
Table 10.2: Forecast for the ROW Prescription Migraine Medicine Market (2025-2031)
Table 10.3: Market Size and CAGR of Various type in the ROW Prescription Migraine Medicine Market (2019-2024)
Table 10.4: Market Size and CAGR of Various type in the ROW Prescription Migraine Medicine Market (2025-2031)
Table 10.5: Market Size and CAGR of Various application in the ROW Prescription Migraine Medicine Market (2019-2024)
Table 10.6: Market Size and CAGR of Various application in the ROW Prescription Migraine Medicine Market (2025-2031)
Table 10.7: Trends and Forecast for the Middle Eastern Prescription Migraine Medicine Market (2019-2031)
Table 10.8: Trends and Forecast for the South American Prescription Migraine Medicine Market (2019-2031)
Table 10.9: Trends and Forecast for the African Prescription Migraine Medicine Market (2019-2031)
Table 11.1: Product Mapping of Prescription Migraine Medicine Suppliers Based on Segments
Table 11.2: Operational Integration of Prescription Migraine Medicine Manufacturers
Table 11.3: Rankings of Suppliers Based on Prescription Migraine Medicine Revenue
Table 12.1: New Product Launches by Major Prescription Migraine Medicine Producers (2019-2024)
Table 12.2: Certification Acquired by Major Competitor in the Global Prescription Migraine Medicine Market

02-2729-4219

+886-2-2729-4219

License/价格

FAQ

偏头痛处方药市场报告：趋势、预测和竞争分析（至2031年）

Prescription Migraine Medicine Market Report: Trends, Forecast and Competitive Analysis to 2031

目录

第一章执行摘要

第二章 市场概览

第三章：市场趋势与预测分析

4. 全球偏头痛处方药市场（按类型划分）

5. 全球偏头痛处方药市场（按应用划分）

第六章 区域分析

7. 北美偏头痛处方药市场

8. 欧洲偏头痛处方药市场

9. 亚太地区偏头痛处方药市场

10. 世界其他地区（ROW）偏头痛处方药市场

第十一章 竞争分析

第十二章：机会与策略分析

第十三章：价值链中主要企业的概况

第十四章附录